ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Employees - 9980,
CEO - Mr. Michael J. Farrell BE, MBA, SM,
Sector - Healthcare,
Country - US,
Market Cap - 36.38B
Altman ZScore(max is 10): 13.26, Piotroski Score(max is 10): 9, Working Capital: $2267904000, Total Assets: $7566822000, Retained Earnings: $5779375000, EBIT: 1598437000, Total Liabilities: $2020689000, Revenue: $5021529000
AryaFin Target Price - $224.75 - Current Price $248.14 - Analyst Target Price $271.72
Ticker | RMD |
Index | S&P 500 |
Curent Price | 248.14 |
Change | -2.06% |
Market Cap | 36.38B |
Average Volume | 1.10M |
Income | 1.31B |
Sales | 5.02B |
Book Value/Share | 37.76 |
Cash/Share | 6.36 |
Dividend Est | 2.21 (0.89%) |
Dividend TTM | 2.12 (0.85%) |
Dividend Ex-Date | May 08, 2025 |
Employees | 9980 |
Moving Avg 20days | 2.73% |
Moving Avg 50days | 9.20% |
Moving Avg 200days | 5.34% |
Shares Outstanding | 146.87M |
Earnings Date | Apr 23 AMC |
Inst. Ownership | 65.80% |
Price/Earnings | 27.86 |
Forwad P/E | 23.46 |
PE Growth | 1.90 |
Price/Sales | 7.25 |
Price/Book | 6.57 |
Price/Cash | 39.01 |
Price/FCF | 23.19 |
Quick Ratio | 2.49 |
Current Ratio | 3.41 |
Debt/Equity | 0.15 |
Return on Assets | 18.26% |
Return on Equity | 25.81% |
Return on Investment | 20.69% |
Gross Margin | 57.87% |
Ops Margin | 32.10% |
Profit Margin | 26.15% |
RSI | 63.91 |
BETA(β) | 0.79 |
From 52week Low | 38.30% |
From 52week High | -5.67% |
EPS | 8.91 |
EPS next Year | 10.58 |
EPS next Qtr | 2.48 |
EPS this Year | 22.96% |
EPS next 5 Year | 14.65% |
EPS past 5 Year | 19.83% |
Sales past 5 Year | 12.49% |
EPS Y/Y | 37.23% |
Sales Y/Y | 9.54% |
EPS Q/Q | 21.67% |
Sales Q/Q | 7.92% |
Sales Surprise | 0.28% |
EPS Surprise | -0.34% |
ATR(14) | 5.98 |
Perf Week | 0.20% |
Perf Month | 17.67% |
Perf Quarter | 5.81% |
Perf Year | 12.81% |
Perf YTD | 8.50% |
Target Price | 271.72 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer